<DOC>
	<DOC>NCT01202617</DOC>
	<brief_summary>The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients</brief_summary>
	<brief_title>Seroquel XR in the Long Term Treatment of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month Severe cerebro and cardiovascular disease, severe hepatic impairment, gravidity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Seroquel XR</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>relapse prevention</keyword>
</DOC>